Biotest Pharmaceuticals Corporation Sustainability Profile
Biotest Pharmaceuticals Corporation, commonly referred to as Biotest, is a prominent player in the biopharmaceutical industry, headquartered in the United States. Founded in 1946, the company has established itself as a leader in the development and production of high-quality plasma-derived therapies and biotherapeutics, primarily focusing on immunology and haematology. With major operational regions across North America and Europe, Biotest is renowned for its innovative products, including immunoglobulins and clotting factors, which are essential for treating various medical conditions. The company’s commitment to quality and patient care has earned it a strong market position, marked by significant achievements in research and development. Biotest continues to advance the field of biopharmaceuticals, making a meaningful impact on patients' lives worldwide.
DitchCarbon Score
How does Biotest Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest Pharmaceuticals Corporation's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest Pharmaceuticals Corporation's reported carbon emissions
Biotest Pharmaceuticals Corporation, headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. Consequently, there are no documented reduction targets or climate pledges at this time. Despite the lack of specific emissions data, Biotest Pharmaceuticals Corporation is part of an industry increasingly focused on sustainability and climate commitments. As a current subsidiary, it may align with broader corporate sustainability initiatives, although specific details regarding such initiatives are not provided. In summary, while Biotest Pharmaceuticals Corporation has not disclosed its carbon emissions or reduction targets, it operates within a sector that is progressively prioritising climate action and emissions reduction.
How Carbon Intensive is Biotest Pharmaceuticals Corporation's Industry?
How Carbon Intensive is Biotest Pharmaceuticals Corporation's Location?
Biotest Pharmaceuticals Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biotest Pharmaceuticals Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
